Dinner traffic falls about 6% among regular GLP-1 users, restaurant strategist says

Dinner traffic at U.S. restaurants fell about 6% among consumers who take GLP-1 drugs regularly, and that decline translates to roughly a 0.4% drop in overall restaurant dinner sales, according to Dana Baggett, executive director of restaurant client strategy at RRD, a firm that works with more than 200 restaurant brands ^[1]. Dinner at fast-food chains has taken the brunt of the damage so far ^[1].

Where the pullback shows up

The effect is not spread evenly across the day. Lunch "hasn't been impacted," Baggett said. Breakfast has taken a hit, especially among higher-income GLP-1 users, showing up as fewer sugary coffee drinks and doughnuts ^[1]. Snacking matters to limited-service chains such as McDonald's and Taco Bell, where it accounts for 12% of spending, according to Bank of America Global Research ^[1].

Survey data points the same direction. About 70% of GLP-1 users who report eating fewer calories said they are snacking less, and about 60% said they are dining out less often, according to an EY-Parthenon survey conducted last spring. Roughly 45% of respondents who said they are eating and drinking less also said they are drinking less alcohol ^[1]. UBS Evidence Lab found about half of GLP-1 users report consuming fewer calories ^[1]. KPMG data cited in the report found users consume 21% fewer calories on average and spend nearly a third less on groceries ^[1].

Not every estimate is that modest. Bernstein surveys indicate restaurant visit frequency among GLP-1 users can fall by as much as 45%, depending on the food category and the occasion, analyst Danilo Gargiulo wrote in a recent research note ^[1]. That is a much larger figure than the 0.4% overall dinner sales effect Baggett described. Domino's CEO Russell Weiner told analysts last month that the pizza chain has not yet seen GLP-1 drugs affect its sales ^[1].

Adoption keeps rising

About one in eight U.S. adults is currently taking a GLP-1 drug such as Ozempic or Zepbound, and 18% say they have taken one at some point, according to the KFF Health Tracking Poll conducted from Oct. 27 to Nov. 2 ^[1]. J.P. Morgan estimates more than 30 million Americans could be on a GLP-1 by 2030, up from 10 million in 2026, and that growing use could wipe out $30 billion to $55 billion in annual food and beverage sales as soon as 2030 ^[1]. Novo Nordisk launched its Wegovy pill in January, and Eli Lilly has said it plans to roll out its own oral drug this year ^[1].

Food and restaurant companies are adjusting. PepsiCo has released protein-packed Doritos and fiber-rich SunChips and Smartfood popcorn; CEO Ramon Laguarta told analysts there are "more opportunities than threats, but there are both" ^[1]. Chipotle launched grab-and-go protein cups in December, and Olive Garden added a Lighter Portions menu that Darden CEO Rick Cardenas said gives all customers more options ^[1]. Nestle updated the packaging of its Vital Pursuit frozen line to say "GLP-1 friendly" and plans to expand into beverages, including protein shakes, Nestle USA CEO Marty Thompson said ^[1].

"I think there shouldn't be this panic out there in the marketplace, but this is a trend that's not going away," Baggett said ^[1].

Why it matters for patients

Menus and portion sizes are shifting around the eating habits of people on GLP-1 medications. Restaurants are testing smaller servings, higher-protein items and lower-sugar drinks ^[1]. For people who eat out while taking these drugs, that can mean more packaged options that match how they already eat, though whether any specific item fits an individual's needs varies.

The nutrition points behind the trend are the ones GLP-1 users often hear about: protein to help prevent muscle loss, fiber for gut health and digestion, and hydration to ease side effects such as nausea and headaches ^[1]. The CNBC report measures restaurant traffic and sales, not health outcomes, and it does not include data on whether menu changes affect anyone's symptoms, nutrition or weight. No standard definition of a "GLP-1 friendly" label has been reported.

It is also worth noting that the headline numbers are averages. A 6% dinner-traffic decline among consistent users and a 0.4% decline in total dinner sales describe group behavior, and Domino's reported seeing no effect at all on its business, so individual habits clearly differ ^[1].

What happens next

J.P. Morgan projects more than 30 million Americans on a GLP-1 by 2030, and Eli Lilly has said its oral drug is coming this year ^[1]. Baggett said pressure on restaurant traffic will grow as the number of consistent users rises ^[1]. Whether the 0.4% dinner-sales figure holds, grows or shrinks as adoption changes has not been disclosed.